RxDoctor Payments Data

Arjun Kanwal, MD

Cardiovascular Disease · Fairfax, VANPI 1992200521

Payments from drug & device makers

$11,087in general payments, 2019–2025

Across 80 payments — averaging $138.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$10K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$297
  • Novartis$253
  • AstraZeneca$134
  • Astellas Pharma US Inc$99
  • Novo Nordisk$88
  • plus $428 from 9 others

What the payments were for

  • Consulting fees$1,0209%
  • Speaking & faculty fees$8,16074%
  • Food & beverage$1,80816%
  • Education$991%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,087 in reported general payments places this provider in the 80th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$74,893
Medicare patients
701
Services billed
1,252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban18$27,000
Metoprolol Succinate19$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$27,00018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →